You are here

Article Text

Article menu
Download PDFPDF
Interpretations
How to use: creatine kinase
  1. Tanmoy Chakrabarty1,
  2. Sandya Tirupathi2,
  3. Andrew Thompson3
  1. 1 Department of Paediatric Neurology, Royal Belfast Hospital for Sick Children, Belfast, UK
  2. 2 Department of Paediatric Neurology, Belfast Health and Social Care Trust, Belfast, Belfast, UK
  3. 3 Department of Paediatrics, Royal Belfast Hospital for Sick Children, Belfast, UK
  1. Correspondence to Dr Tanmoy Chakrabarty, Paediatric Neurology, Royal Belfast Hospital for Sick Children, Belfast BT12 6BE, UK; t.chak{at}yahoo.co.uk

Abstract

Creatine kinase (CK) remains an essential tool for assessment of muscular weakness and pain in children despite the advent of advanced diagnostic tests in this field. It is also useful in diagnosing and monitoring various other conditions. This article will explore the physiology of CK and clinical situations where the estimation of CK can help the clinicians’ decision-making process with the diagnosis and management of these conditions. Some clinical scenarios are used to highlight how the tests can be used in different clinical situations. The role of CK as a biomarker of myocardial injury has been purposefully omitted in this article.

  • creatine Kinase
  • paediatric
  • muscular dystrophies
  • interpretation

https://doi.org/10.1136/archdischild-2019-317184

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors TC conceptualised the idea, performed literature search and wrote the manuscript. ST reviewed and edited the manuscript and also is the guarantor. AT reviewed and edited the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Commissioned; externally peer reviewed.

    • Patient consent for publication Not required.